157 related articles for article (PubMed ID: 10597870)
1. Cardiac effects of ebastine and other antihistamines in humans.
Moss AJ; Morganroth J
Drug Saf; 1999; 21 Suppl 1():69-80; discussion 81-7. PubMed ID: 10597870
[TBL] [Abstract][Full Text] [Related]
2. A review of the cardiac systemic side-effects of antihistamines: ebastine.
Moss AJ; Chaikin P; Garcia JD; Gillen M; Roberts DJ; Morganroth J
Clin Exp Allergy; 1999 Jul; 29 Suppl 3():200-5. PubMed ID: 10444238
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.
Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW
Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.
Hey JA; del Prado M; Kreutner W; Egan RW
Arzneimittelforschung; 1996 Feb; 46(2):159-63. PubMed ID: 8720305
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
Chaikin P; Gillen MS; Malik M; Pentikis H; Rhodes GR; Roberts DJ
Br J Clin Pharmacol; 2005 Mar; 59(3):346-54. PubMed ID: 15752381
[TBL] [Abstract][Full Text] [Related]
6. Problems of heart rate correction in assessment of drug-induced QT interval prolongation.
Malik M
J Cardiovasc Electrophysiol; 2001 Apr; 12(4):411-20. PubMed ID: 11332559
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
8. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.
Gillen MS; Miller B; Chaikin P; Morganroth J
Br J Clin Pharmacol; 2001 Aug; 52(2):201-4. PubMed ID: 11488779
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
10. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
Huang MY; Argenti D; Wilson J; Garcia J; Heald D
Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
[TBL] [Abstract][Full Text] [Related]
12. Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects.
Hey JA; del Prado M; Egan RW; Kreutner W
Ann Allergy Asthma Immunol; 1996 May; 76(5):476. PubMed ID: 8630724
[No Abstract] [Full Text] [Related]
13. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders.
Wiseman LR; Faulds D
Drugs; 1996 Feb; 51(2):260-77. PubMed ID: 8808167
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
[TBL] [Abstract][Full Text] [Related]
15. Ebastine: an update of its use in allergic disorders.
Hurst M; Spencer CM
Drugs; 2000 Apr; 59(4):981-1006. PubMed ID: 10804044
[TBL] [Abstract][Full Text] [Related]
16. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
[TBL] [Abstract][Full Text] [Related]
17. The effect of food on the bioavailability of ebastine.
Pentikis HS; Huang MY; Dorr MB; Heald DL
Am J Ther; 1997; 4(2-3):80-4. PubMed ID: 10423596
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
19. Effects of H1 antihistamines on animal models of QTc prolongation.
Gras J; Llenas J
Drug Saf; 1999; 21 Suppl 1():39-44; discussion 81-7. PubMed ID: 10597867
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of ebastine in children.
Simons FE; Watson WT; Simons KJ
J Pediatr; 1993 Apr; 122(4):641-6. PubMed ID: 8096545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
